Loading patent…
AssigneesThe First Affiliated Hospital of the Chinese People's Liberation Army Army Medical University, Chengdu Seventh People's Hospital
InventorsJin CHAI, Zhongyong JIANG, Jingjing DING, Xiaoxun ZHANG
Estimating the term…
An application of a biomarker in preparing metabolic dysfunction-associated steatotic liver disease classification products is provided. The biomarker is any one or more of the following: a combination of liver protein biomarkers, a combination of serum protein biomarkers, a combination of serum lipid biomarkers, a combination of serum metabolite biomarkers, a combination of serum protein, lipid and metabolite biomarkers, a combination of urine protein biomarkers, a combination of urine metabolite biomarkers, and a combination of urine protein and metabolite biomarkers; and the metabolic dysfunction-associated steatotic liver disease is divided into a metabolically active type, a high-risk type of cirrhosis and a high-risk type of hepatocellular carcinoma. The combinations of biomarkers provided by the present disclosure have a good effect on the diagnosis of three MASLD molecular subtypes, which provides technical support for the classification and diagnosis of MASLD.
A method for preparing metabolic dysfunction-associated steatotic liver disease classification products, comprising using a biomarker, wherein the biomarker is one or more of the following:
A combination of liver protein biomarkers for a metabolic dysfunction-associated steatotic liver disease classification, wherein the combination of the liver protein biomarkers is a combination of LAMB1, FLNC, and ERCC3.
A combination of serum protein biomarkers for a metabolic dysfunction-associated steatotic liver disease classification, wherein the combination of the serum protein biomarkers is a combination of CPM, NUCB1, KRT17, and CLC.
A combination of serum lipid biomarkers for a metabolic dysfunction-associated steatotic liver disease classification, wherein the combination of the serum lipid biomarkers is a combination of FFA (18:1), FFA (19:0), Cer (t18:0/24:0), and TG (16:0_16:0_18:1).
A combination of serum metabolite biomarkers for a metabolic dysfunction-associated steatotic liver disease classification, wherein the combination of the serum metabolite biomarkers is a combination of FFA (11:1), PC (18:1 (9Z)/20:4 (5Z, 8Z, 11Z, 14Z)), DG (18:3 (9Z,12Z,15Z)/22:4 (7Z, 10Z, 13Z, 16Z)/0:0), Carboxyphosphamide, and DG (14:1 (9Z)/24:1 (15Z)/0:0).
A combination of serum protein biomarkers, serum lipid biomarkers, and serum metabolite biomarkers for a metabolic dysfunction-associated steatotic liver disease classification, wherein the combination of the serum protein biomarkers, the serum lipid biomarkers, and the serum metabolite biomarkers is a combination of 17alpha, 20alpha-Dihydroxycholesterol, DG (20:1 (11Z)/18:1 (11Z)/0:0), TG (16:0_16:1_18:1), PC (18:1 (9Z)/20:4 (5Z,8Z,11Z,14Z)), and RTN4RL2.
A combination of urine protein biomarkers for a metabolic dysfunction-associated steatotic liver disease classification, wherein the combination of the urine protein biomarkers is a combination of LBP, CD300A, and GCHF.
A combination of urine metabolite biomarkers for a metabolic dysfunction-associated steatotic liver disease classification, wherein the combination of the urine metabolite biomarkers is a combination of 7alpha-Hydroxyandrost-4-ene-3,17-dione, 27-Hydroxycholesterol, PE-NMe (15:0/15:0), Chenodeoxycholic acid sulfate, and PE (18:1 (11Z)/20:0).
A combination of urine protein biomarkers and urine metabolite biomarkers for a metabolic dysfunction-associated steatotic liver disease classification, wherein the combination of the urine protein biomarkers and the urine metabolite biomarkers is a combination of ICOSLG, 7alpha-Hydroxy-5beta-cholstan-3-one, CYBRD1, FCGR3A, and ACAN.
Dependencies are inferred from the claim text.